ADAP

Adaptimmune Therapeutics PLC

Add to Watchlist

Advanced Chart

0.059

-0.01(-14.514%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.0669

Open

0.0665

VWAP

0.06

Vol

41.12M

Mkt Cap

15.61M

Low

0.0588

Amount

2.57M

EV/EBITDA(TTM)

Total Shares

255.56M

17.88M

EV/OCF(TTM)

P/S(TTM)

0.27

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

15.10M

+107.28%

-0.070

-61.11%

15.93M

+394.35%

-0.020

-93.33%

12.93M

-68.38%

-0.050

+400%

Estimates Revision

The market is revising Downward the revenue expectations for Adaptimmune Therapeutics plc (ADAP) for FY2025, with the revenue forecasts being adjusted by -18.75% over the past three months. During the same period, the stock price has changed by -78.43%.

Revenue Estimates for FY2025

Revise Downward

-18.75%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.1%

In Past 3 Month

Stock Price

Go Down

-78.43%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast ADAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAP is 0.35 USD with a low forecast of 0.09 USD and a high forecast of 0.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

4 Hold

2 Sell

Moderate Sell

Current: 0.059

Low

0.09

Averages

0.35

High

0.50

Current: 0.059

Low

0.09

Averages

0.35

High

0.50

H.C. Wainwright

Arthur He

Buy -> Neutral

downgrade

2025-07-29

Reason

H.C. Wainwright

Arthur He

Price Target

2025-07-29

downgrade

Buy -> Neutral

Reason

H.C. Wainwright analyst Arthur He downgraded Adaptimmune to Neutral from Buy without a price target after the company agreed to sell Tecelra, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for up to $85M. With only preclinical assets remaining in the pipeline, Adaptimmune has now meaningful near-term catalysts, the analyst tells investors in a research note.

Guggenheim

Buy

Neutral

downgrade

2025-07-29

Reason

Guggenheim

Price Target

2025-07-29

downgrade

Buy

Neutral

Reason

Guggenheim downgraded Adaptimmune to Neutral from Buy.

Mizuho

Outperform -> Neutral

downgrade

$0.50

2025-06-25

Reason

Mizuho

Price Target

$0.50

2025-06-25

downgrade

Outperform -> Neutral

Reason

Mizuho downgraded Adaptimmune to Neutral from Outperform with a 50c price target.

Mizuho

Outperform -> Neutral

downgrade

2025-06-25

Reason

Mizuho

Price Target

2025-06-25

downgrade

Outperform -> Neutral

Reason

Mizuho downgraded Adaptimmune to Neutral from Outperform with a price target of 50c, down from $1.50. The firm says the company's solvency and future sustainability are its main concerns. With management trying its best to balance the need to maximize the Tecelra launch while keeping spending low enough to keep the company financially afloat, uncertainty on the outcome of the bank-assisted strategic review, and a lack of catalysts, Adaptimmune's outlook "simply seems too challenging," the analyst tells investors in a research note.

Barclays

Peter Lawson

Underweight

downgrade

2025-05-14

Reason

Barclays

Peter Lawson

Price Target

2025-05-14

downgrade

Underweight

Reason

Barclays analyst Peter Lawson lowered the firm's price target on Adaptimmune to 46c from $1 and keeps an Underweight rating on the shares. The company's Q1 product revenue was roughly in line with consensus but it evaluated strategic options ongoing to address its constrained capital position, the analyst tells investors in a research note.

Wells Fargo

Equal Weight

downgrade

2025-05-14

Reason

Wells Fargo

Price Target

2025-05-14

downgrade

Equal Weight

Reason

Wells Fargo lowered the firm's price target on Adaptimmune to $1 from $1.50 and keeps an Equal Weight rating on the shares. While the Tecelra launch is ramping up, the firm sees balance sheet risk in the near term, absent positive outcomes from the ongoing exploration of strategic options, given the limited cash position and quarterly cash burn.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Adaptimmune Therapeutics PLC (ADAP.O) is -0.28, compared to its 5-year average forward P/E of -3.58. For a more detailed relative valuation and DCF analysis to assess Adaptimmune Therapeutics PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.58

Current PE

-0.28

Overvalued PE

-0.26

Undervalued PE

-6.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.62

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

8.36

Undervalued EV/EBITDA

-7.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

45.88

Current PS

0.30

Overvalued PS

144.12

Undervalued PS

-52.36